CD274 and breast cancer: To validate the implications of low PD-L1 CPS in predicting response to Nivolumab, larger cohort studies should examine PD-L1 expression longitudinally in BC patients receiving ICIs to assess variability and analyze how prior therapies (e.g., targeted inhibitors) affect PD-L1 regulation and ICI sensitivity.